Klotho (αKlotho) is a single-pass transmembrane protein discovered as a longevity gene — Klotho-deficient mice show premature aging (vascular calcification, osteopenia, infertility, atrophy). αKlotho acts as the obligate co-receptor for FGF23, converting promiscuous FGFRs (1c, 3c, 4) into FGF23-specific high-affinity receptors in target tissues (kidney proximal tubule + parathyroid). Phosphate axis: FGF23 is secreted by osteocytes/osteoblasts in response to ↑serum Pi + ↑calcitriol + ↑PTH. FGF23-Klotho-FGFR1c on kidney → ↓NaPi-2a/2c (PT brush border) → phosphaturia; FGF23 also ↓CYP27B1 + ↑CYP24A1 → ↓calcitriol (counter-regulating Pi absorption). In parathyroid: FGF23 → ↓PTH (acute). Three-hormone interplay: PTH ↑Pi excretion + ↑calcitriol + ↑bone resorption; FGF23 ↑Pi excretion + ↓calcitriol; calcitriol ↑Ca + Pi absorption + ↑FGF23 secretion. CKD-MBD: declining GFR → Pi retention → ↑FGF23 (compensatory) → ↓calcitriol → secondary hyperparathyroidism → tertiary HPT; ↑FGF23 also independently associated with CV mortality + LVH. Klotho also has hormonal soluble form (shed by ADAM10/17 + γ-secretase) — circulates as anti-aging factor (regulates Ca channels, oxidative stress, Wnt, IGF-1). Loss of soluble Klotho in CKD → contributes to vascular calcification + cognitive decline. Therapeutics: phosphate binders (sevelamer, lanthanum, calcium carbonate, sucroferric oxyhydroxide) lower dietary Pi load; calcimimetics (cinacalcet, etelcalcetide) — CaSR agonists → ↓PTH; calcitriol/paricalcitol for CKD-MBD with monitoring; burosumab (anti-FGF23 mAb) for X-linked hypophosphatemic rickets + tumor-induced osteomalacia. Cross-links: calcium phosphate pth axis (PTH + Ca arm), vitamin d metabolism (calcitriol), bone remodeling rank rankl (osteocyte source).
Organ Systems
renal
endocrine
musculoskeletal
Pathway Steps
↑serum Pi + ↑calcitriol → osteocyte FGF23 secretion — via PHEX / DMP1 regulation; FAM20C kinase phosphorylates Ser180 → cleavage protection. FGF23 is a bone-derived hormone secreted by osteocytes in response to rising serum phosphate and calcitriol (1,25-D). It is the body’s principal phosphate-lowering signal — the afferent limb of a feedback loop against phosphate excess, which is why FGF23 rises early and markedly in chronic kidney disease.
FGF23 + αKlotho (PT cell) → FGFR1c high-affinity activation — via Klotho is the co-receptor that confers FGF23 specificity to otherwise promiscuous FGFRs. FGF23 binds FGF receptors only weakly on its own; it requires the co-receptor αKlotho to activate FGFR1c with high affinity. Because Klotho is expressed in only a few tissues (notably kidney), it confers tissue specificity — restricting FGF23’s action to Klotho-expressing organs despite ubiquitous FGFRs.
FGF23-Klotho-FGFR1c (kidney PT) → ↓NaPi-2a / NaPi-2c brush-border transporters — via → phosphaturia (primary endocrine effect). In the proximal tubule, FGF23-Klotho-FGFR1c signaling downregulates the brush-border phosphate transporters NaPi-2a/NaPi-2c, reducing phosphate reabsorption and promoting phosphaturia. This is the central phosphate-excreting action of the axis, opposing dietary phosphate loading.
FGF23 (kidney) → ↓CYP27B1 + ↑CYP24A1 — via → ↓calcitriol production + ↑inactivation; secondary mineral homeostasis effect. FGF23 also suppresses calcitriol: it inhibits CYP27B1 (1α-hydroxylase) and induces CYP24A1 (the catabolic 24-hydroxylase), lowering active vitamin D. This dampens intestinal phosphate and calcium absorption — coordinating renal and intestinal handling, and contributing to the low calcitriol of CKD.
FGF23 (parathyroid) → ↓PTH (acute) — via short-term; chronic FGF23 ↑ → parathyroid resistance + PTH escape. Acutely, FGF23 acts on the parathyroid to suppress PTH — an additional feedback arm. In advanced CKD, however, the parathyroid becomes FGF23-resistant (Klotho is downregulated), which together with low calcitriol drives the secondary hyperparathyroidism of kidney disease.
membrane Klotho → soluble Klotho (sKL) by ADAM10/17 + γ-secretase shedding — via circulating hormone — Ca-channel modulation, anti-fibrotic, oxidative stress reduction. The Klotho ectodomain is shed by ADAM10/17 and γ-secretase to release soluble Klotho (sKL), a circulating, FGF23-independent factor acting on ion channels, growth-factor signaling, and anti-aging/anti-fibrotic processes. Declining Klotho with age and in CKD makes it a biomarker and therapeutic target.